Atlas Trials

A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

Clinical trial NCT00912964 · COMPLETED

Trial details

NCT number
NCT00912964
Sponsor
Astellas Pharma Inc
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Urinary Bladder, Overactive
Start date
2009-04-28
Primary completion
2010-04-27
Enrollment
2030

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.